top of page

OrbiMed's Carl Gordon shares his take on biotech's 2025 and what could be ahead for the sector in 2026

  • Dec 15, 2025
  • 1 min read

He discusses the causes of the rapid bounce biotech has witnessed over the last handful of months, his take on 2026, including the IPO environment, private vs public companies, areas of interest, and more.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page